Nabriva Therapeutics PLC (NASDAQ:NBRV)
| 0.5841 Delayed Data As of Sep 18 |  -0.0009 / -0.15%Today’s Change | 0.49 Today|||52-Week Range 2.35 | -55.75% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $83.7M |
Company Description
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Contact Information
Nabriva Therapeutics Plc 25-28 North Wall Quay Dublin Dublin 1 |
Employees
Shareholders
| Individual stakeholders | 9.02% |
| Mutual fund holders | 13.14% |
| Other institutional | 12.01% |
Top Executives
| Theodore R. Schroeder | Chief Executive Officer & Director |
| Steven P. Gelone | President & Chief Operating Officer |
| Gary L. Sender | Chief Financial Officer |
| Jennifer Schranz | Chief Medical Officer |
| William Q. Sargent | Vice President-Commercial Strategy & Access |
